Back to the main directory
Company Analysis / Equity
- Kazia Therapeutics - New asset to target tumor lymphangiogenesis by Edison Investment Research
- KERING: As anticipated Gucci caught up in Q1, but even more than expected | BUY Top Picks | EUR680 VS. EUR650 (+9%) by Bryan Garnier
- ROCHE: Even stronger-than-expected divergence between Pharma and Diagnostics | BUY | CHF360(+17%) by Bryan Garnier
- EKINOPS (Conviction BUY, TP EUR9.5) | Launch portable satellite communication solution with IEC: by Bryan Garnier
- BIOCARTIS (BUY, TP EUR8) | MSI test submission for FDA 510(k): by Bryan Garnier
- MORPHOSYS (BUY, TP EUR115) | Phase III initiation of tafasitamab in patients with indolent lymphoma by Bryan Garnier
- ATOS: Moving in the right direction despite weak Q1 2021 sales | BUY | EUR90(+48%) by Bryan Garnier
- HERMÈS INTL. (NEUTRAL, TP EUR790) | Q1 sales grew 44% at same FX in Q1 vs Q1 20: by Bryan Garnier
- Thin Film Electronics - Continued progress on commercialisation by Edison Investment Research
- Nicox - Key programmes continue to advance by Edison Investment Research
- RÉMY COINTREAU | SELL | EUR128 FY 2020/21 sales in line with expectations, EBIT should increase by 10% by Bryan Garnier
- SANOFI (BUY, TP EUR112) | Positive phase III for nirsevimab. A good for Sanofi and AstraZeneca: by Bryan Garnier
- UCB (BUY, TP EUR133) | Bemikizumab demonstrates a clear superiority over Cosentyx: by Bryan Garnier
- Fidelity European Trust - Not persuaded by great (rotation) expectations by Edison Investment Research
- Leclanché - Termination of coverage by Edison Investment Research
- Monde Nissin Pre-IPO - Peer comparison for Meat Alternative business by Aequitas Research
- Tetragon Financial Group - TFG Asset Management grows in AUM and value by Edison Investment Research
- RhoVac - COVID-19 vaccines versus RV001 by Edison Investment Research
- Media and Games Invest - Full steam ahead, with two M&A deals in Q121 by Edison Investment Research
- 1Spatial - Momentum continues; raising FY22 estimates by Edison Investment Research
- Checkit - On the front foot by Edison Investment Research
- SPIE: Decent start of the year – return of the acquisitions | BUY Top Picks | EUR23(+9%) by Bryan Garnier
- HEINEKEN: Reiterating the sell case | SELL | EUR80(-16%) by Bryan Garnier
- NEL - BUY | NOK33(+36%) Record order backlog promise an acceleration by Bryan Garnier
- BIOCARTIS (BUY, TP EUR8) | Expansion for Idylla AZ collab marks real progress in CDx model : by Bryan Garnier